Drug Trial Radar · NCT04317248
"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
600
Planned (sponsor's estimate)
Start
Apr 1, 2020
Primary completion
Apr 30, 2022
Study completion Apr 30, 2022
Sponsor
- Lead sponsor
- Yuehua HuangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sun Yat-sen University; Nanfang Hospital, Southern Medical University
- First posted
- Mar 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The effect of anti-tumor treatment is not satisfying in HBV-related hepatocellular carcinoma (HBV-HCC) for reasons that HBV-HCC carries highly heterogeneous antigens to facilitate cancer cells escaping from immune surveillance and constructs an immunosuppressive microenvironment. Correspondingly, multiple signals loaded dendritic cells vaccine can efficiently present T cells with antigens of HCC sensitize their antitumor properties meanwhile low dose cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Therefore, we put forward a new scientific therapy called "multiple signals loaded dendritic cells vaccine combined low dose of cyclophosphamide" combining with radical surgery or TACE or targeted agents for patients with hepatocellular carcinoma to prolong their survival time.
Conditions
- Hepatocellular Carcinoma
Interventions
CyclophosphamideDrug
Intravenous drip,250mg/m\^2 per time,two days before each times of MSDCV therapy,total 6 times, in order to improve the immunosuppressive microenvironment of tumor,reduce CD4+CD25+FOXP3+regulatory T cells (Tregs)
Multiple Signals loaded Dendritic Cells VaccineBiological
one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free-Survival (PFS), monthTime frame: 240 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University Cancer center
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
The Third Affiliated Hospital of Zhongshan University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.